Literature DB >> 6675167

Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy.

H Sandberg-Gertzén, M Ryde, G Järnerot.   

Abstract

The behaviour of a single 1-g oral dose of azodisal sodium (ADS) given to 10 healthy volunteers with an ileostomy was studied. Blood samples were drawn at various times, and urine and ileostomy fluid were collected during the following 24 h. ADS was absorbed to a very low extent, giving a maximum serum concentration of less than or equal to 5.1 micrograms/ml within 0.5-2 h after the dose was ingested. A mean of 0.3% of the dose was excreted in unchanged form with the urine. The metabolites 5-ASA and Ac-5-ASA could not be found in serum or urine. Of the ADS dose given, 100.2% (SD +/- 14.8%) could be recovered in the ileostomy fluid. The results indicate that ADS is a potentially useful drug for the local treatment of ulcerative colitis, 5-ASA being the active part of the molecule.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6675167     DOI: 10.3109/00365528309181568

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  21 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.

Authors:  N Mahmud; D G Weir; D Kelleher
Journal:  Ir J Med Sci       Date:  1999 Oct-Dec       Impact factor: 1.568

4.  Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study.

Authors:  N Mahmud; M A Kamm; J L Dupas; D P Jewell; C A O'Morain; D G Weir; D Kelleher
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 5.  Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Authors:  S B Hanauer; G Stathopoulos
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

6.  New salicylates as maintenance treatment in ulcerative colitis.

Authors:  G Järnerot
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

7.  Secretory effect of azodisalicylate (azodisal sodium) on the short circuited mucosa of the rat ileum in vitro.

Authors:  K J Goerg; R Wanitschke; P H Diehl; K H Meyer zum Büschenfelde
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

Review 8.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

9.  Stability of disodium azodisalicylate (olsalazine) and metabolites in urine and faeces stored at different temperatures.

Authors:  R A van Hogezand; A van Schaik; P A van Hees; J H van Tongeren
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

10.  Effect of olsalazine on sodium-dependent bile acid transport in rat ileum.

Authors:  A Chawla; P I Karl; R N Reich; G Narasimhan; G A Michaud; S E Fisher; B L Schneider
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.